baber/WOPTO huggingface dataset:
Patent NZ-571373-A (NZ)
Title: System and method for food preparation
Inventor: BAARMAN DAVID W
IPC: H05B6/06
Filed: 2007-01-31
Abstract: A device identification system for use with a device having an inductive secondary comprises a power supply including an inductive primary and being capable of driving the inductive primary at a plurality of frequencies and measuring means for measuring a response of the inductive secondary to each of the frequencies. The plurality of responses forms a frequency response profile. The system further comprises memory means for storing a plurality of device identifiers each associated with one of the frequency response profiles. The device identifiers include information regarding the use of the device. The system further comprises a processor means operatively coupled to the power supply, the measuring means, and the memory means. The processor means is for compiling the frequency response profile, for selecting from the memory means the device identifier and the associated use information as a function of the frequency response profile, and for controlling the power supply in accordance with the associated use information. device identification system is part of a food preparation system.
Patent NZ-577720-A (NZ)
Title: Substituted oxindole derivatives and their use as vasopressin receptor ligands
Inventor: NETZ ASTRID
IPC: A61P25/00
Filed: 2007-12-28
Abstract: Disclosed is a compounds of the general formula (I) in which R5 is hydrogen, methoxy or ethoxy; R6 is hydrogen or methoxy; R7 is hydrogen, methyl, ethyl, n-propyl or isopropyl; X2 is N or CH; X3 is N or CH; and where X2 and X3 are not simultaneously N; and the pharmaceutically acceptable salts, tautomeric forms and prod rugs thereof. Also disclosed are a medicament comprising a compound of formal (I) ; a pharmaceutical composition comprising a compound of formula (I) and the use of a compound of formula (I) in the manufacture of a medicament for treating at least one vasopressin-dependent disease, diabetes, insulin resistance, nocturnal enuresis, incontinence, diseases in which blood coagulation disorders occur, and/or for delaying micturition, hypertension, pulmonary hyper-tension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemias of the heart, disorders of the renal system, edemas, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, disorders of the gastrointestinal tract, gastritic vasospasm, hepatocirrhosis, gastric and intestinal ulcer, emesis, emesis occurring duringchemotherapy, and/or travel sickness. Examples of compound include N-[5-Cyano-1-[(2, 4-dimethoxyphenyl)sulphonyl} -3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl} -4-(1-methylpiperidin-4-yl)piperazine-1-carboxamide; (+)-N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carboxamide and (-)-N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carboxamide.
Patent NZ-579875-A (NZ)
Title: Template-fixed peptidomimetics
Inventor: DEMARCO STEVEN J
IPC: A61K38/12
Filed: 2007-02-28
Abstract: Disclosed is a Cyclo(-Tyr-His-X-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr- Gln-Lys-DPro- Pro), with a disulfide bond between Cys4 and Cysl 11, and pharmaceutically acceptable salts thereof, with X being Ala or Tyr. Also disclosed is the use of compound for the manufacture of a CXCR4 antagonizing medicament.
Patent NZ-582876-A (NZ)
Title: Tailored multi-site combinatorial assembly of polynucleotides
Inventor: TAN XUQIU
IPC: C12N15/09
Filed: 2008-07-31
Abstract: A method of creating mutations in polynucleotides that comprises: (a) Adding three of more primers to a double stranded polynucleotide in a single PCR reaction mixture. The primers do not overlap and each contains at least one mutation. At least one primer is a forward primer that anneals to the minus strand of the template and at least one primer is a reverse primer that anneals to the plus strand of the template; and (b) Subjecting the reaction mixture to a polymerase extension reaction to yield a plurality of extended modified polynucleotides. The method can be performed without employing a ligation step prior to transforming the extended modified polynucleotides into a cell. The template polynucleotide can be a circular dsDNA molecule such as a plasmid or a BAC.
Patent NZ-590146-A (NZ)
Title: Antibodies which bind an epitope comprising two different monomers of the P2X7 receptor
Inventor: BARDEN JULIAN ALEXANDER
IPC: A61K38/17
Filed: 2009-07-03
Abstract: Disclosed is an antibody for binding to an epitope of a P2X7 receptor the epitope being formed of: - a first region in the form of a region of a first monomer of a P2X7 receptor; and - a second region in the form of a region of a second monomer of the receptor; wherein the first and second regions are formed in the receptor by cis isomerisation of a proline residue at a position equivalent to 210 of SEQ ID No: 1 of a monomer of the receptor; and wherein the first and second regions are arranged adjacent each other in the receptor thereby permitting binding of an antigen binding site of the antibody to the first and second regions forming the epitope. Further disclosed is a peptide including an N terminal region and a C terminal region, the N and C terminal regions each being defined by Nand C terminal residues, wherein: - the N terminal region includes a sequence of HNYTTRNIL (SEQ ID NO: 2) or fragment thereof of at least 4 residues; - the C terminal region includes a C terminal residue that is proline, alanine, or glycine; wherein the C terminal residue of the N terminal region is covalently linked to an N terminal residue of the C terminal region; wherein the C terminal residue of the C terminal region is connected to a further peptide by a linker having a length of about 10 to 30 angstroms; and wherein said further peptide consists of a sequence KTTNVSLYPGYNFRYAKYVKENNVEKRTLlKVFGIRFDILVFGTGGKFD or fragment thereof of at least 4 residues.
Patent NZ-591488-A (NZ)
Title: Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
Inventor: CHANG TONG-HSUAN
IPC: C07K16/18
Filed: 2008-09-07
Abstract: Disclosed is a human monoclonal antibody or antigen binding portion thereof that specifically binds an epitope comprising an extended Type I chain comprising Leb, wherein said epitope is expressed on a cancer cell, wherein said antibody or antigen binding portion thereof does not bind to Ley , and wherein the antibody has a heavy chain variable region having the amino acid sequence that has 80%-100% identity with SEQ ID NO 15, and a light chain variable region having the amino acid sequence that has 80%-100% identity with SEQ ID NO 17.
Patent NZ-592135-A (NZ)
Title: Side curtain including slidable and pivoting reinforcing straps
Inventor: BROWN GREGORY ALAN
IPC: B60J7/10
Filed: 2010-01-20
Abstract: A side curtain arrangement, for a truck or trailer body (10), includes a side curtain (12) and a plurality of reinforcing straps (14) extending between top and bottom edges of the curtain at intervals along the curtain. The straps are connectable to a top part of the body to be slidable longitudinally of the body and pivotable parallel to the plane of the curtain. The lower end of each strap has an engagement member for engaging the body at or adjacent a floor of the body when the strap is pivoted in a first direction to enable the straps to be held or locked by the engagement members engaging the body. Means interconnecting the lower ends of the straps facilitate simultaneous pivotal movement of the straps both in the first direction, and also in an opposite second direction to enable the straps to be released or unlocked by the engagement members disengaging from the body.
Patent NZ-593749-A (NZ)
Title: Soluble icam-1 as biomarker for prediction of therapeutic response
Inventor: ACRES BRUCE
IPC: G01N33/68
Filed: 2010-01-18
Abstract: Provided is an ex-vivo method for testing whether a patient will respond therapeutically to a method of treatment comprising administration of an immunogenic composition, wherein the testing method comprises the steps of: - measuring levels of sICAM-1 in a blood sample from the patient, wherein low levels of sICAM-1 indicate that the patient will develop a prophylactic or therapeutic response towards the immunogenic composition with low levels of sICAM-1 being fewer than about 300 ng/ml.
Patent NZ-600352-A (NZ)
Title: Electrical plug safety device
Inventor: CANANZI DARREN MARK
IPC: F16P1/00
Filed: 2010-11-22
Abstract: 600352 An electrical plug safety device (10) is disclosed. The device comprises a body (16) having apertures for receiving pins of an electrical plug (12). A securing member (32) is provided within the body (16) to engage with surfaces of the pins when the pins are received in the apertures. Engagement between the securing member (32) and the sides of the pins restricts removal of the plug (12) from the body (16). When sufficient force is applied to disengage the securing member (32) the securing member (32) will not re-engage with a pin inserted into the body (16). Hence, the device prevents reuse of the device once removed.
Patent NZ-601682-A (NZ)
Title: Lock assembly including bolt hold back function
Inventor: NEWMAN DONALD JOHN
IPC: E05B63/08
Filed: 2011-02-22
Abstract: 601682 The specification relates to a lock assembly (1) including a housing (2) and a latch bolt (3) that is moveable between an extended and retracted position under the influence of a biasing means (7). A retainer means (29) is adjustable between a first position, second position and third position. The retainer means (29) prevents movement of the latch bolt (3) from the retracted position when in first position, and does not prevent movement of the latch bolt (3) from the retracted position when in a second or third position. The retainer means (29) achieves a function often referred to as a hold back function.
Patent NZ-603694-A (NZ)
Title: Container from fibre based board and a method for producing such a container
Inventor: HEISKANEN ISTO
IPC: B32B27/10
Filed: 2011-05-19
Abstract: 603694 The present disclosure relates to a container made from fiber based board wherein the container comprises a sleeve and a bottom, said bottom comprises polymer coated board, at least the inner side of said sleeve is uncoated and the sleeve is formed by sealing two edges of the sleeve together along a side seam. The disclosure further relates to a method for producing said container.
Patent NZ-604013-A (NZ)
Title: Comparison of protein samples
Inventor: LEE DAVID H
IPC: G01N31/00
Filed: 2011-06-16
Abstract: Disclosed is a method of characterising two samples of an unlabelled protein, the method comprising: (i) providing a sample of a labelled protein, having a known amino acid sequence, wherein at least one amino acid in the protein is replaced with an isotopically labelled amino acid; (ii) providing a first sample comprising the protein, wherein the protein is not isotopically labelled; (iii) mixing the labelled protein and the unlabelled protein from the first sample to form a mixture; (iv) subjecting the mixture to protein digestion to form a first digest; (v) subjecting the first digest to bottom-up Liquid Chromatography-Mass Spectroscopy to form a first spectra including intensities of individual mass-to-charge (m/z) peaks corresponding to individual peptide fragments of the labelled protein and the unlabelled protein from the first sample; (vi) summing the intensities of the m/z peaks associated with a peptide fragment of the labelled protein; (vii) summing the intensities of the m/z peaks for the corresponding peptide fragment of the unlabelled protein from the first sample; (viii) calculating the ratio of the sum of the m/z peaks for the peptide fragment of the unlabelled protein from the first sample over the sum of the m/z peaks for the peptide fragment of the labelled protein; (ix) providing a second sample comprising the protein, wherein the protein is not isotopically labelled; (x) mixing the labelled protein and the unlabelled protein from the second sample to form a mixture; (xi) subjecting the mixture to protein digestion to form a second digest; (xii) subjecting the second digest to bottom-up Liquid Chromatography-Mass Spectroscopy to form a second spectra including intensities of individual mass-to-charge (m/z) peaks corresponding to individual peptide fragments of the labelled protein and the unlabelled protein from the second sample; (xiii) summing the intensities of the m/z peaks associated with the peptide fragment of the labelled protein corresponding to the peptide fragment of (vi); (xiv) summing the intensities of the m/z peaks for the corresponding peptide fragment of the unlabelled protein from the second sample; (xv) calculating the ratio of the sum of the m/z peaks for the peptide fragment of the unlabelled protein from the second sample over the sum of the m/z peaks for the peptide fragment of the labelled protein; (xvi) calculating the ratio of the ratio calculated in (xv) over the ratio calculated in (viii); thereby characterizing two samples of the unlabelled protein.
Patent NZ-610638-A (NZ)
Title: Pharmaceutical compositions comprising radezolid
Inventor: LI DANPING
IPC: A61P31/04
Filed: 2011-11-21
Abstract: Discloses a pharmaceutical composition comprising prior to mixing: (a) radezolid or a pharmaceutically acceptable salt, ester or prodrug thereof as described herein; { b) a hydroxypropylmethylcellulose polymer; (c) a disintegrant; (d) a lubricant; (e) optionally, a filler; and (f) a binder.
Patent NZ-614460-A (NZ)
Title: Vaccines and compositions against streptococcus pneumoniae
Inventor: GIERAHN TODD
IPC: A61K39/09
Filed: 2012-01-20
Abstract: Disclosed is a vaccine formulation comprising a pharmaceutically acceptable carrier and a first polypeptide comprising an SP1912 amino acid sequence in combination with an amino acid sequence of either SP2108 or SP0148, of S. pneumoniae. Also disclosed is the use of the vaccine for treating a subject suffering from or susceptible to S. pneumoniae infection.
Patent NZ-618277-A (NZ)
Title: Uracil or thymine derivative for treating hepatitis c
Inventor: HUTCHINSON DOUGLAS K
IPC: C07D417/10
Filed: 2008-09-17
Abstract: Disclosed are Uracil or Thymine derivatives of formula (I) useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2H)-yl)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1-(2H)-yl)2-methoxy-styryl-phenyl)methanesulfonamide. Also disclosed are crystalline forms of the compounds and processes for preparing the compounds and the crystal forms.
Patent NZ-618331-A (NZ)
Title: Stable formulations of a hyaluronan-degrading enzyme
Inventor: VAUGHN DANIEL EDWARD
IPC: A61P5/50
Filed: 2012-06-15
Abstract: Discloses a stable co-formulation composition, wherein: the composition has a pH of between or between about 6.8 and 7.8; and the composition comprises: a) an insulin or insulin analogue; b) a hyaluronidase; c) NaCl; d) a stabilising agent or agents; and e) one or more preservative agents comprising a phenolic preservative, whereby the composition is stable for at least 6 months at a temperature from or from about 2°C to 8°C, inclusive, and/or for at least 14 days at a temperature from or from about 20°C to 30°C, inclusive.
Patent NZ-624360-A (NZ)
Title: Methods of reducing milk somatic cell count
Inventor: SUE MCCOARD
IPC: A61K31/198
Filed: 2014-05-02
Abstract: A method of decreasing somatic cell count in the milk from a lactating ruminant comprises administering effective therapeutically effective amount of L-arginine, NCG or NAG to elevate blood plasma arginine levels in the ruminant. The L-arginine, NCG or NAG is administered during the gestation time period and/or during the lactation phase post parturition. Also disclosed is a method of improving mammary gland health in a ruminant as measured via somatic cell count in milk produced comprising administering effective therapeutically effective amount of L-arginine, NCG or NAG to elevate blood plasma arginine levels. The L-arginine, NCG or NAG administered during the gestation time period and/or during the lactation phase post parturition
Patent NZ-630908-A (NZ)
Title: Heterocyclic compounds and methods of their use
Inventor: MCCARTHY THOMAS DAVID
IPC: C07D217/26
Filed: 2014-07-08
Abstract: The disclosure relates generally to compounds that are useful in antagonizing the angiotensin II type 2 (AT2) receptor. More particularly, the invention relates to substituted isoquinoline compounds and their use as AT2 receptor antagonists. Pharmaceutical compositions comprising the compounds and their use in modulating the AT2 receptor and therapies that require modulation of the AT2 receptor are described.
Patent NZ-705048-A (NZ)
Title: Frame assembly for sheet material
Inventor: HONEY IAN
IPC: E06B3/673
Filed: 2007-08-21
Abstract: A frame assembly for sheet material. The frame assembly has a number of inner frame sections each with a recess for receiving the sheet material. The inner frame sections can be fitted around the periphery of the sheet material. The frame assembly has a first outer frame for receiving the sheet material with the inner frame sections fitted thereon, and a second outer frame to be applied to the sheet material with the inner frame sections fitted thereon, a and a fastener to connect the first and second outer frames together. The first and second outer frames together define a space for receiving the inner frame sections. The first and second outer frames clamp the inner frame sections to capture the inner frame sections and thereby also capture the sheet material that the inner frame sections are fitted thereon. A geometry of the inner frame sections is such that the inner frame sections have a neck portion and a base portion. The neck portion includes a mouth of the recess. The outer cross-sectional shape of the inner frame sections is such that the base portion is wider than the neck portion.
Patent NZ-705820-A (NZ)
Title: Modulation of hepatitis b virus (hbv) expression
Inventor: MCCALEB MICHAEL L
IPC: C07H21/02
Filed: 2012-04-20
Abstract: Disclosed is a compound, comprising a single-stranded modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 17, 50, 1340, and 1379, wherein: (a) the single-stranded modified oligonucleotide is at least 90% complementary to SEQ ID NO: 1; and (b) the modified oligonucleotide comprises: a gap segment consisting of linked deoxynucleosides; a 5’ wing segment consisting of linked nucleosides; and a 3’ wing segment consisting of linked nucleosides; wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar; wherein the sequences are as defined in the specification.
Patent NZ-710686-A (NZ)
Title: Breathable gas apparatus with humidifier
Inventor: VIRR ALEXANDER
IPC: B29C63/00
Filed: 2004-06-21
Abstract: A breathable gas supply apparatus for treatment of respiratory disorders comprising a flow generator with an air inlet (807) on a rear wall (803), the air inlet configured to provide a supply of ambient air to a blower of the flow generator; a water tub (698) with a first air opening, a second air opening, a top portion, a side surface configured to face the rear wall in use and having the second air opening therein and a bottom portion, the bottom portion having a heat conducting surface; a base (602, 803) with a heater (800), the base being configured to receive the water tub; a lid (700); a rotatably engageable catch (646) for the lid, the catch securing the water tub in the base in use; a seal (699) between the lid and the top portion of the water tub; an outlet pipe for connection with an air delivery tube in use; a first gas flow port aligned with and in a facing arrangement with the first air opening; a second gas flow port in a facing arrangement with the second air opening; and a peripheral seal (722) between the second gas flow port and the second air opening to create a sealed air path therebetween. The water tub and the base include complementary configurations (698, 632) that facilitate alignment of the water tub with respect to the base to ensure alignment between the second air opening and the second gas flow port. When the catch is engaged, downwards pressure is maintained on the water tub to maintain heat-transfer contact between the bottom portion of the water tub and the heater. The water tub can be removed and refilled with water without requiring disengagement of the air delivery tube from the outlet pipe. The first air opening, the second air opening, the first gas flow port and the second gas flow port are part of a flow path between the flow generator and the outlet pipe.
Patent NZ-711782-A (NZ)
Title: Improvements to work attachment assemblies
Inventor: DOHERTY JEREMY GLEN
IPC: E02F9/24
Filed: 2008-11-03
Abstract: A connection assembly to provide a releasable connection between a device on a work attachment and control system. The work attachment is secured to a machine via a coupler. The assembly includes a first mounting having a first set of connectors, and a second mounting having a second set of connectors configured to engage with the first set of connectors. The assembly has at least one guard to protect one of the sets of connectors. The guard and/or the mountings are configured to move with respect to each other to expose the sets of connectors and allow these to engage. The connection assembly includes at least one impact absorbers.
Patent NZ-721637-A (NZ)
Title: Gypsum plaster-based material containing an edta metal complex
Inventor: CHUDA KATARZYNA
IPC: C04B22/00
Filed: 2014-12-23
Abstract: The invention relates to a gypsum plaster-based material, in particular a gypsum plasterboard intended for the interior decoration of dwellings, containing an EDTA metal complex. The invention relates to the use of said material in order to reduce the amount of volatile organic compounds in the atmosphere inside dwellings, offices or public buildings.
Patent NZ-721992-A (NZ)
Title: System and method for managing the power output of a photovoltaic cell
Inventor: MCNAMARA ROBERT P
IPC: H02S40/32
Filed: 2015-02-21
Abstract: A solar cell management system and method for increasing the efficiency and power output of a solar cell and methods for making and using the same. The management system and method utilise an electric field across an individual solar cell, an array of solar cells configured as a panel, or a group of solar panels. Specifically utilised is a voltage signal comprising a series of voltage pulses with a positive magnitude, each of the voltage pulses comprising an on state for generating an external electric field across the photovoltaic devices, and further comprising an off cycle between adjacent voltage pulses. The imposed electric field exerts a force on both the electrons and holes created by light incident on the solar cell and accelerates the electron-hole pairs towards the electrodes of the solar cell. Compared to conventional solar cells, these accelerated electron-hole pairs travel a shorter distance from creation and spend less time within the solar cell material, therefore the electron-hole pairs have a lower likelihood of recombining within the cells’ semiconductor’s material. This reduction in the electron-hole recombination rate results in an overall increase in the solar cells’ efficiency and greater power output.